Iterum Property Plant And Equipment Gross from 2010 to 2024

ITRM Stock  USD 2.03  0.02  0.98%   
Iterum Therapeutics Property Plant And Equipment Gross yearly trend continues to be very stable with very little volatility. Property Plant And Equipment Gross is likely to drop to about 347.7 K. During the period from 2010 to 2024, Iterum Therapeutics Property Plant And Equipment Gross quarterly data regression pattern had sample variance of 3.4 T and median of  747,000. View All Fundamentals
 
Property Plant And Equipment Gross  
First Reported
2017-12-31
Previous Quarter
363 K
Current Value
363 K
Quarterly Volatility
3.2 M
 
Covid
Check Iterum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iterum Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 521.7 K, Interest Income of 1 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 25 K, Dividend Yield of 0.0 or Days Sales Outstanding of 10.3 K. Iterum financial statements analysis is a perfect complement when working with Iterum Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Iterum Therapeutics Correlation against competitors.

Latest Iterum Therapeutics' Property Plant And Equipment Gross Growth Pattern

Below is the plot of the Property Plant And Equipment Gross of Iterum Therapeutics PLC over the last few years. It is Iterum Therapeutics' Property Plant And Equipment Gross historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iterum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Property Plant And Equipment Gross10 Years Trend
Very volatile
   Property Plant And Equipment Gross   
       Timeline  

Iterum Property Plant And Equipment Gross Regression Statistics

Arithmetic Mean1,083,780
Geometric Mean688,878
Coefficient Of Variation170.08
Mean Deviation884,296
Median747,000
Standard Deviation1,843,345
Sample Variance3.4T
Range7.4M
R-Value0.04
Mean Square Error3.7T
R-Squared0
Significance0.89
Slope15,650
Total Sum of Squares47.6T

Iterum Property Plant And Equipment Gross History

2024347.7 K
2023366 K
2022353 K
2021377 K
2020421 K
20197.7 M
2018700 K

About Iterum Therapeutics Financial Statements

Iterum Therapeutics investors utilize fundamental indicators, such as Property Plant And Equipment Gross, to predict how Iterum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Property Plant And Equipment Gross366 K347.7 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:
Check out the analysis of Iterum Therapeutics Correlation against competitors.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.76)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(5.56)
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.